ES2989669T3 - Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana - Google Patents

Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana Download PDF

Info

Publication number
ES2989669T3
ES2989669T3 ES20158066T ES20158066T ES2989669T3 ES 2989669 T3 ES2989669 T3 ES 2989669T3 ES 20158066 T ES20158066 T ES 20158066T ES 20158066 T ES20158066 T ES 20158066T ES 2989669 T3 ES2989669 T3 ES 2989669T3
Authority
ES
Spain
Prior art keywords
seq
hil
binding
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20158066T
Other languages
English (en)
Spanish (es)
Inventor
Onur Boyman
Natalia Arenas-Ramirez
Chao Zou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Application granted granted Critical
Publication of ES2989669T3 publication Critical patent/ES2989669T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES20158066T 2014-07-10 2015-07-10 Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana Active ES2989669T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14176619 2014-07-10

Publications (1)

Publication Number Publication Date
ES2989669T3 true ES2989669T3 (es) 2024-11-27

Family

ID=51162588

Family Applications (2)

Application Number Title Priority Date Filing Date
ES20158066T Active ES2989669T3 (es) 2014-07-10 2015-07-10 Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana
ES15759938T Active ES2779977T3 (es) 2014-07-10 2015-07-10 Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15759938T Active ES2779977T3 (es) 2014-07-10 2015-07-10 Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana

Country Status (9)

Country Link
US (2) US10894828B2 (enExample)
EP (2) EP3166973B1 (enExample)
JP (1) JP7209464B2 (enExample)
CN (1) CN106604932B (enExample)
AU (1) AU2015287227B2 (enExample)
CA (1) CA2954476C (enExample)
DK (1) DK3166973T3 (enExample)
ES (2) ES2989669T3 (enExample)
WO (1) WO2016005950A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018014150A2 (en) * 2016-01-11 2018-12-11 Novartis Ag immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
GB201621806D0 (en) * 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
CN110913873A (zh) * 2017-02-23 2020-03-24 希望之城 用于cd8+t细胞的体内扩增并预防或治疗gvhd的方法
EP3600421A4 (en) * 2017-03-23 2021-01-06 The Trustees of The University of Pennsylvania ANTI-C5A ANTIBODIES AND USES OF THEM
JP7057980B2 (ja) * 2017-05-25 2022-04-21 インスティテュート フォー ベーシック サイエンス 抗－ヒトインターロイキン－２抗体及びその用途
US12454561B2 (en) 2018-03-19 2025-10-28 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
EP4090377A1 (en) 2020-01-13 2022-11-23 Synaffix B.V. Conjugates of antibodies an immune cell engagers
CN115397852B (zh) 2020-02-16 2023-08-11 奥罗斯生物科学公司 工程化抗il-2抗体
IL297329A (en) * 2020-04-22 2022-12-01 Merck Sharp & Dohme Llc Dimeric interleukin-2 beta gamma receptor-biased human interleukin-2 conjugates conjugated to soluble non-peptide polymers.
KR20230048151A (ko) * 2020-08-18 2023-04-10 유니버시타트 취리히 Cd25 편향된 항-il-2 항체
JP2024506022A (ja) 2021-02-08 2024-02-08 シンアフィックス ビー．ブイ． 多機能性抗体
JP2024539749A (ja) 2021-10-14 2024-10-29 ラッティコン （スージョウ） バイオファーマシューティカルズ カンパニー リミテッド 新規な抗体－サイトカイン融合タンパク質及びその製造方法と使用
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins
CN119912559B (zh) * 2025-01-22 2025-12-26 贵州中医药大学 一种新冠病毒变异株jn.1刺突s蛋白的单链抗体及其应用
CN119775409B (zh) * 2025-03-05 2025-07-11 深圳真实生物医药科技有限公司 靶向sost的抗体及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK174501B1 (da) 1983-12-23 2003-04-28 Hoffmann La Roche Fremgangsmåde til fremstilling af interleukin-2
JPS62269698A (ja) * 1986-03-17 1987-11-24 エフ．ホフマン　―　ラ　ロシュ　アーゲー Ｉｌ−２蛋白質に対するモノクロ−ナル抗体
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998006842A1 (en) 1996-08-16 1998-02-19 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
JP2006512391A (ja) 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
NZ563213A (en) 2005-06-01 2009-07-31 Micromet Ag Anti-IL2 antibodies
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
US20100310501A1 (en) * 2006-02-16 2010-12-09 Onur Boyman Methods for Improving Immune Function and Methods for Prevention or Treatment of Disease in a Mammalian Subject
CN101045923B (zh) * 2006-03-31 2011-11-23 沈阳三生制药有限责任公司 生产一种白细胞介素类似物的方法
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
LT3339323T (lt) 2010-08-12 2020-02-10 Eli Lilly And Company Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas
US9266938B2 (en) 2011-02-10 2016-02-23 Roche Glycart Ag Mutant interleukin-2 polypeptides
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof

Also Published As

Publication number Publication date
CN106604932A (zh) 2017-04-26
CA2954476C (en) 2023-09-19
JP2017525343A (ja) 2017-09-07
CN106604932B (zh) 2024-12-10
US10894828B2 (en) 2021-01-19
CA2954476A1 (en) 2016-01-14
US20210230269A1 (en) 2021-07-29
EP3693389B1 (en) 2024-09-04
EP3693389A1 (en) 2020-08-12
WO2016005950A1 (en) 2016-01-14
EP3166973A1 (en) 2017-05-17
AU2015287227A1 (en) 2017-02-09
AU2015287227B2 (en) 2021-02-18
EP3693389C0 (en) 2024-09-04
EP3166973B1 (en) 2020-02-19
ES2779977T3 (es) 2020-08-21
DK3166973T3 (da) 2020-04-06
JP7209464B2 (ja) 2023-01-20
EP3693389A9 (en) 2021-04-07
US20170183403A1 (en) 2017-06-29
AU2015287227A8 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
ES2989669T3 (es) Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana
CN113166246B (zh) 一种抗体及其用途
US10081680B2 (en) Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies
ES2952132T3 (es) Nuevo anticuerpo anti-pad4
CN117120477A (zh) 针对密蛋白18a2和cd3的双特异性抗体及其应用
JP7711208B2 (ja) Ｄｌｌ３に対する結合分子及びその使用
TWI882142B (zh) 抗FXI/FXIa抗體、其抗原結合片段及醫藥用途
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
KR102428255B1 (ko) 위암의 검출 및 치료를 위한 조성물 및 방법
CN112094348A (zh) 抗人Tim3抗体或其功能性片段及其应用
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN115210263A (zh) 抗axl抗体和组合物
WO2024017326A1 (zh) 抗gprc5d纳米抗体及其应用
ES2907717T3 (es) Proteínas y usos
CN115335402B (zh) 特异性抗原结合分子,其制备方法及医药用途
CN118215685A (zh) 抗gucy2c抗体及其应用
RU2837590C9 (ru) Антитела против axl и композиции
RU2837590C1 (ru) Антитела против axl и композиции
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
US20190194319A1 (en) Anti-ascl1 antibodies and methods of use
WO2018213680A1 (en) Diagnostic antibodies and methods of use
HK40049006A (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof
HK40049006B (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof
HK40081002A (en) Anti-axl antibodies and compositions